The pharmacokinetics of orally administered fudosteine in healthy Chinese volunteers

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 31, Issue 2, 2006, Pages 65-71

  Jiao, H Y ^a   Zhang, Z J ^a   Xu, F G ^a   Tian, Y ^a   Zhang, B B ^a   Chen, Y ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Dose; Fudosteine; Gender difference; Pharmacokinetics

Indexed keywords

9 FLUORENYLMETHYL CHLOROFORMATE; FUDOSTEINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHINESE; CONTROLLED STUDY; DERIVATIZATION; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM; DRUG HALF LIFE; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MULTIPLE DRUG DOSE; NORMAL HUMAN; SEX DIFFERENCE; SINGLE DRUG DOSE;

EID: 33746673859     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03191121     Document Type: Article

References (15)

1. Takahashi K, Mizuno H, Ohno H, Kai H, Isohama Y, Takahama K, et al. (1998): Effects of SS320A, a new cysteine derivative, on the change in the number of goblet cells induced by isoproterenol in rat tracheal epithelium. Jpn J. Pharmacol. 77, 71-77.
2. Takahashi K, Mizuno H, Ohno H, Takeuchi M, Nagaoka S, Kai H, et al. (1998): Effects of SS320A, a new cysteine derivative, on the change in the number of goblet cells induced by bacterial endotoxin in rat tracheal epithelium. Environ. Toxicol. Pharmacol. 5, 173-178.
3. Rogers DF. (1994): Airway goblet cells: responsive and adaptable frontline defenders. Eur. Respir. J. 7, 1690-1706.
4. Lundgren JD, Shelhamer JH. (1990): Pathogenesis of airway mucus hypersecretion. J. Allergy Clin. Immunol. 85, 399-417.
5. Steiger D, Hotchkiss J, Bujaj L, Harkema J, Basbaum C. (1995): Concurrent increases in the storage and release of mucin-like molecules by rat airway epithelial cells in response to bacterial endotoxin. Am. J. Respir. Cell. Mol. Biol. 12, 307-314.
6. Komatsu H, Yamaguchi S, Komorita N, Goto K, Takagi S, Ochi H, Okumoto T. (2005): Inhibition of endotoxin- and antigen-induced airway inflammation by fudosteine, a mucoactive agent. Pulmon. Pharmacol. Ther. 18, 121-127.
7. Guidance for Industry, Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), May 2001.
8. Dimmitt DC, Choo YS, Martin LA, Arumugham T, Hahne WF, Weir SJ. (1999): Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2. Biopharm. Drug. Dispos. 20, 41-48.
9. Liu XD, Xie L, Liang Y, Li L, LU T. (2003): Gender difference in ranolazine pharmacokinetics in rats. Eur. J. Drug Metab. Pharmacokinet. 28(2), 119-123.
10. Zhu X, Shin WG. (2005): Gender differences in pharmacokinetics of oral warfarin in rats. Biopharm. Drug. Dispos. 26, 147-150.
11. Lee YS, Han KS, Lee MG. (1999): Gender differences in pharmacokinetics and pharmacodynamics of azosemide in rat. Biopharm. Drug. Dispos. 20, 225-229.
12. Yonkers KA, Kando JC, Cole JO, Blumenthal S. (1992): Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am. J. Psychiatry. 149, 587-595.
13. Abad-Santos F, Novalbos J, Galvez-Mugica MA, Gallego-Sandin S, Almeida S, Vallee F, et al. (2005): Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study. Pharmacol. Res. 51, 445-442.
14. Hunt CM, Westerkam WR, Stave GM. (1992): Effect of age and gender on the activity of human hepatic CYP3A. Biochem. Pharmacol. 44, 275-283
15. Harris RZ, Benet LZ, Schwartz JB. (1995): Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 50, 222-239.